Relationship between serum IGF-1 and skeletal muscle IGF-1 mRNA expression to phosphocreatine recovery after exercise in obese men with reduced GH

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages 617-625

  Hamarneh, Sulaiman R ^a   Murphy, Caitlin A ^a   Shih, Cynthia W ^a,b   Frontera, Walter ^c,d,e   Torriani, Martin ^a   Irazoqui, Javier E ^a   Makimura, Hideo ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD COLLEGE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

^e UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATINE PHOSPHATE; GLUCOSE; GROWTH HORMONE; INSULIN; MESSENGER RNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; NUCLEAR RESPIRATORY FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; HUMAN GROWTH HORMONE;

ABDOMINAL OBESITY; ADULT; ANALYTICAL PARAMETERS; ANKLE BRACHIAL INDEX; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE TITRATION; EXERCISE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; LEAN BODY WEIGHT; MALE; MIDDLE AGED; MITOCHONDRIAL DYNAMICS; MUSCLE BIOPSY; MUSCLE LEVEL; MUSCLE MITOCHONDRION; OUTCOME ASSESSMENT; PARACRINE SIGNALING; PHOSPHOCREATINE RECOVERY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTING ENERGY EXPENDITURE; SKELETAL MUSCLE; TREATMENT DURATION; TRUNK FAT; WAIST CIRCUMFERENCE; ADOLESCENT; BLOOD; GENETICS; METABOLISM; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; EXERCISE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MITOCHONDRIA, MUSCLE; MUSCLE, SKELETAL; OBESITY, ABDOMINAL; PHOSPHOCREATINE; RNA, MESSENGER; YOUNG ADULT;

EID: 84922522978     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2711     Document Type: Article

References (46)

1. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002; 51: 2944-2950.
2. Fleischman A, Johnsen S, Systrom DM, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007; 292: E1666-E1673.
3. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA. 2003; 100: 8466-8471.
4. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat Genet. 2003; 34: 267-273.
5. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-γ coactivator 1 α (PGC-1α): transcriptional coactivator and metabolic regulator. Endocr Rev. 2003; 24: 78-90.
6. Kang C, Li Ji L. Role of PGC-1α signaling in skeletal muscle health and disease. Ann NY Acad Sci. 2012; 1271: 110-117.
7. Cheah JS, Chua SP, Ho CL. Ultrastructure of the skeletal muscles in acromegaly-before and after hypophysectomy. Am J Med Sci. 1975; 269: 183-187.
8. Makimura H, Stanley TL, Sun N, Hrovat MI, Systrom DM, Grinspoon SK. The association of growth hormone parameters with skeletal muscle phosphocreatine recovery in adult men. J Clin Endocrinol Metab. 2011; 96: 817-823.
9. Befroy DE, Shulman GI. Magnetic resonance spectroscopy studies of human metabolism. Diabetes. 2011; 60: 1361-1369.
10. Lanza IR, Bhagra S, Nair KS, Port JD. Measurement of human skeletal muscle oxidative capacity by 31P-MR spectroscopy: a cross-validation with in vitro measurements. J Magn Reson Imaging. 2011; 34: 1143-1150.
11. Larson-Meyer DE, Newcomer BR, Hunter GR, Joanisse DR, Weinsier RL, Bamman MM. Relation between in vivo and in vitro measurements of skeletal muscle oxidative metabolism. Muscle Nerve. 2001; 24: 1665-1676.
12. Sahlin K, Harris RC, Hultman E. Resynthesis of creatine phosphate in human muscle after exercise in relation to intramuscular pH and availability of oxygen. Scand J Clin Lab Invest. 1979; 39: 551-558.
13. Kemp GJ, Thompson CH, Barnes PR, Radda GK. Comparisons of ATP turnover in human muscle during ischemic and aerobic exercise using 31P magnetic resonance spectroscopy. Magn Reson Med. 1994; 31: 248-258.
14. Short KR, Moller N, Bigelow ML, Coenen-Schimke J, Nair KS. Enhancement of muscle mitochondrial function by growth hormone. J Clin Endocrinol Metab. 2008; 93: 597-604.
15. Bredella MA, Gerweck AV, Lin E, et al. Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity. J Clin Endocrinol Metab. 2013; 98: 3864-3872.
16. Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. J Clin Endocrinol Metab. 2014; 99: 338-343.
17. Hosseini Ghomi R, Bredella MA, Thomas BJ, Miller KK, Torriani M. Modular MR-compatible lower leg exercise device for whole-body scanners. Skeletal Radiol. 2011; 40: 1349-1354.
18. Roussel M, Bendahan D, Mattei JP, Le Fur Y, Cozzone PJ. 31P magnetic resonance spectroscopy study of phosphocreatine recovery kinetics in skeletal muscle: the issue of intersubject variability. Biochim Biophys Acta. 2000; 1457: 18-26.
19. Dietrichson P, Coakley J, Smith PE, Griffiths RD, Helliwell TR, Edwards RH. Conchotome and needle percutaneous biopsy of skeletal muscle. J Neurol Neurosurg Psychiatry. 1987; 50: 1461-1467.
20. Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest. 1975; 35: 609-616.
21. Evans WJ, Phinney SD, Young VR. Suction applied to a muscle biopsy maximizes sample size. Med Sci Sports Exerc. 1982; 14: 101-102.
22. Makimura H, Stanley T, Mun D, You SM, Grinspoon S. The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J Clin Endocrinol Metab. 2008; 93: 4254-4260.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419.
24. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr. 1990; 51: 1106-1112.
25. Butler AA, LeRoith D. Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology. 2001; 142: 1685-1688.
26. Yakar S, Wu Y, Setser J, Rosen CJ. The role of circulating IGF-I: lessons from human and animal models. Endocrine. 2002; 19: 239-248.
27. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA. 1999; 96: 7324-7329.
28. Zhang Y, Yuan M, Bradley KM, Dong F, Anversa P, Ren J. Insulinlike growth factor 1 alleviates high-fat diet-induced myocardial contractile dysfunction: role of insulin signaling and mitochondrial function. Hypertension. 2012; 59: 680-693.
29. Dalla Libera L, Ravara B, Volterrani M, et al. Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure. Am J Physiol Cell Physiol. 2004; 286: C138-C144.
30. Vescovo G, Ravara B, Gobbo V, Angelini A, Dalla Libera L. Skeletal muscle fibres synthesis in heart failure: role of PGC-1α, calcineurin and GH. Int J Cardiol. 2005; 104: 298-306.
31. Johannsson G, Mårin P, Lönn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab. 1997; 82: 727-734.
32. Karlsson C, Stenlöf K, Johannsson G, et al. Effects of growth hormone treatment on the leptin system and on energy expenditure in abdominally obese men. Eur J Endocrinol. 1998; 138: 408-414.
33. Franco C, Brandberg J, Lönn L, Andersson B, Bengtsson BA, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab. 2005; 90: 1466-1474.
34. Pasarica M, Zachwieja JJ, Dejonge L, Redman S, Smith SR. Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. J Clin Endocrinol Metab. 2007; 92: 4265-4270.
35. Mekala KC, Tritos NA. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. J Clin Endocrinol Metab. 2009; 94: 130-137.
36. Zurlo F, Larson K, Bogardus C, Ravussin E. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest. 1990; 86: 1423-1427.
37. Møller N, Schmitz O, Pørksen N, Møller J, Jørgensen JO. Doseresponse studies on the metabolic effects of a growth hormone pulse in humans. Metabolism. 1992; 41: 172-175.
38. Møller N, Møller J, Jørgensen JO, et al. Impact of 2 weeks high dose growth hormone treatment on basal and insulin stimulated substrate metabolism in humans. Clin Endocrinol (Oxf). 1993; 39: 577-581.
39. Davidson MB Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev. 1987; 8: 115-131.
40. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolisminhuman subjects. Endocr Rev. 2009; 30: 152-177.
41. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 1990; 322: 223-228.
42. Franco C, Andersson B, Lönn L, Bengtsson BA, Svensson J, Johannsson G. Growth hormone reduces inflammation in postmeno-pausal women with abdominal obesity: a 12-month, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007; 92: 2644-2647.
43. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012; 97: 4769-4779.
44. Warner ET, Wolin KY, Duncan DT, Heil DP, Askew S, Bennett GG. Differential accuracy of physical activity self-report by body mass index. Am J Health Behav. 2012; 36: 168-178.
45. Slootmaker SM, Schuit AJ, Chinapaw MJ, Seidell JC, van Mechelen W. Disagreement in physical activity assessed by accelerometer and self-report in subgroups of age, gender, education and weight status. Int J Behav Nutr Phys Act. 2009; 6: 17.
46. McMurray RG, Ward DS, Elder JP, et al. Do overweight girls over-report physical activity? Am J Health Behav. 2008; 32: 538-546.